Midatech Pharma PLC Company Profile (LON:MTPH)

About Midatech Pharma PLC (LON:MTPH)

Midatech Pharma PLC logoMidatech Pharma PLC is an early-stage biopharmaceutical company that focuses on commercializing and developing products in oncology and other therapeutic areas. The Company's segments include Pipeline Research and Development, and Commercial. The Pipeline Research and Development segment seeks to develop products using the nanomedicine and sustained release technology platforms. The Commercial segment distributes and sells the commercial products. Its products include Zuplenz, Gelclair, Oravig and Soltamox. Zuplenz is an oral soluble film indicated for moderately emetogenic chemotherapy-induced nausea and vomiting (CINV), radiotherapy-induced nausea and vomiting (RINV), and post-operative nausea and vomiting (PONV). Gelclair is a product indicated for the management and relief of pain due to oral mucositis. Oravig is an orally dissolving buccal tablet approved for oral thrush. Soltamox is an oral liquid solution of tamoxifen citrate for the prevention of breast cancer.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: LON:MTPH
  • CUSIP: N/A
  • Web: www.midatechpharma.com/
Capitalization:
  • Market Cap: £50.4 million
  • Outstanding Shares: 48,699,000
Average Prices:
  • 50 Day Moving Avg: GBX 106.92
  • 200 Day Moving Avg: GBX 116.95
  • 52 Week Range: GBX 100 - GBX 189.90
P/E:
  • Trailing P/E Ratio: N/A
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: £6.92 million
  • Price / Sales: 7.28
  • Book Value: GBX 0.94 per share
  • Price / Book: 1.10
Profitability:
  • EBIDTA: ($14,820,000.00)
  • Net Margins: -383.24%
  • Return on Equity: -55.17%
  • Return on Assets: -42.10%
Misc:
  • Average Volume: 29,792 shs.
 
Frequently Asked Questions for Midatech Pharma PLC (LON:MTPH)

What is Midatech Pharma PLC's stock symbol?

Midatech Pharma PLC trades on the London Stock Exchange (LON) under the ticker symbol "MTPH."

Where is Midatech Pharma PLC's stock going? Where will Midatech Pharma PLC's stock price be in 2017?

2 equities research analysts have issued 1-year price targets for Midatech Pharma PLC's shares. Their forecasts range from GBX 140 to GBX 297. On average, they expect Midatech Pharma PLC's share price to reach GBX 218.50 in the next twelve months. View Analyst Ratings for Midatech Pharma PLC.

Who are some of Midatech Pharma PLC's key competitors?

Who are Midatech Pharma PLC's key executives?

Midatech Pharma PLC's management team includes the folowing people:

  • James Neil Phillips, Chief Executive Officer, Director
  • Nicholas John Robbins-Cherry, Finance Director, Director
  • Craig Cook, Chief Operating Officer / Chief Medical Officer
  • Daniel David Palmer Ph.D., Chief Scientific Officer
  • Justin Barry, Head - Manufacturing
  • Tim Sparey, Chief Business Officer
  • Rolf Stahel, Non-Executive Chairman of the Board
  • Simon De Vries, Non-Executive Director
  • John Joseph Johnston, Non-Executive Director
  • Michele Luzi, Non-Executive Director

How do I buy Midatech Pharma PLC stock?

Shares of Midatech Pharma PLC and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Midatech Pharma PLC's stock price today?

One share of Midatech Pharma PLC stock can currently be purchased for approximately GBX 103.50.


MarketBeat Community Rating for Midatech Pharma PLC (LON MTPH)
Community Ranking:  4.5 out of 5 (    )
Outperform Votes:  130 (Vote Outperform)
Underperform Votes:  15 (Vote Underperform)
Total Votes:  145
MarketBeat's community ratings are surveys of what our community members think about Midatech Pharma PLC and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Midatech Pharma PLC (LON:MTPH) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: GBX 218.50

Analysts' Ratings History for Midatech Pharma PLC (LON:MTPH)
Show:
DateFirmActionRatingPrice TargetDetails
5/22/2017N+1 SingerReiterated RatingBuyGBX 140View Rating Details
5/22/2017Panmure GordonReiterated RatingBuyGBX 297View Rating Details
(Data available from 7/27/2015 forward)

Earnings

Earnings History for Midatech Pharma PLC (LON:MTPH)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Midatech Pharma PLC (LON:MTPH)
Current Year EPS Consensus Estimate: $-40.40 EPS

Dividends

Dividend History for Midatech Pharma PLC (LON:MTPH)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Midatech Pharma PLC (LON:MTPH)
Insider Trades by Quarter for Midatech Pharma PLC (LON:MTPH)
Insider Trades by Quarter for Midatech Pharma PLC (LON:MTPH)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/18/2015Phillips,James NeilInsiderBuy960GBX 204£1,958.40
6/26/2015Phillips,James NeilInsiderBuy2,572GBX 3.09GBX 7,947.48
6/24/2015Phillips,James NeilInsiderBuy2,000GBX 2.87GBX 5,740
6/23/2015Robbins-Cherry,NicholasInsiderBuy500GBX 2.88GBX 1,440
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Midatech Pharma PLC (LON:MTPH)
Latest Headlines for Midatech Pharma PLC (LON:MTPH)
Source:
DateHeadline
finance.yahoo.com logoMidatech Pharma Plc: Completion of pre-clinical liver cancer programme
finance.yahoo.com - July 27 at 4:32 AM
finance.yahoo.com logoMidatech Pharma Plc: Trading Update and Notice of Results
finance.yahoo.com - July 18 at 11:59 PM
finance.yahoo.com logoR&D manufacturing site visit for investors and analysts
finance.yahoo.com - June 13 at 6:50 PM
americanbankingnews.com logoPanmure Gordon Reaffirms "Buy" Rating for Midatech Pharma PLC (MTPH)
www.americanbankingnews.com - May 22 at 4:28 PM
americanbankingnews.com logoMidatech Pharma PLC's (MTPH) "Buy" Rating Reaffirmed at N+1 Singer
www.americanbankingnews.com - May 22 at 3:50 PM
finance.yahoo.com logoMidatech Pharma Plc :MTPH-GB: Earnings Analysis: For the six months ended December 31, 2016 : April 26, 2017
finance.yahoo.com - April 26 at 11:36 PM
americanbankingnews.com logoMidatech Pharma PLC (MTPH) Receives "Buy" Rating from Panmure Gordon
www.americanbankingnews.com - April 20 at 7:37 PM
americanbankingnews.com logoPanmure Gordon Reaffirms Buy Rating for Midatech Pharma PLC (MTPH)
www.americanbankingnews.com - April 8 at 6:46 PM
americanbankingnews.com logoMidatech Pharma PLC (MTPH) Scheduled to Post Earnings on Tuesday
www.americanbankingnews.com - April 3 at 1:25 AM
americanbankingnews.com logoMidatech Pharma PLC (MTPH) Rating Reiterated by Panmure Gordon
www.americanbankingnews.com - March 10 at 7:37 PM
finance.yahoo.com logoMidatech Pharma PLC: Midatech Announces Successful Initial Scale-Up of Its Sustained Release Manufacturing Facility
finance.yahoo.com - March 10 at 9:40 AM
finance.yahoo.com logoMidatech Pharma PLC: Trading Update
finance.yahoo.com - January 20 at 7:29 PM
ft.com logo[$$] Biotech and pharma companies hope for better in 2017
www.ft.com - January 6 at 7:24 PM
streetinsider.com logoForm 6-K Midatech Pharma Plc For: Nov 22
www.streetinsider.com - November 22 at 10:29 AM
nasdaq.com logoMidatech Pharma Plc: Commencement of First in Human Immunotherapy Study Using Gold Nanoparticle Technology
www.nasdaq.com - October 1 at 5:36 PM
biz.yahoo.com logoHalf Year 2016 Midatech Pharma PLC Earnings Release - Time Not Supplied
biz.yahoo.com - September 2 at 11:06 AM
uk.finance.yahoo.com logoIs this stock the best buy in its sector following today’s update?
uk.finance.yahoo.com - August 10 at 9:24 AM
msn.com logoMidatech Pharma Plc: Grant funding received to explore Midatech's gold nanoparticle technology in immunotherapy
www.msn.com - July 7 at 6:20 PM
finance.yahoo.com logoMidatech Signs Licensing Agreement With Emergex Vaccines
finance.yahoo.com - January 4 at 2:00 AM
finance.yahoo.com logoMidatech Pharma PLC Director Dealing
finance.yahoo.com - December 18 at 8:56 AM

Social

Social activity is not available for this stock.

Chart

Midatech Pharma PLC (MTPH) Chart for Thursday, July, 27, 2017

This page was last updated on 7/27/2017 by MarketBeat.com Staff